Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Holding the regimen can be complex or lead to errors
A retrospective study showed that HbA1c improved significantly during the first year of treatment and this effect was maintained over four years, although the benefits plateaued after the first year
Carol Wysham reported on 978 patients with type 2 diabetes in the 52-week, phase III AWARD-1 trial who were randomized to dulaglutide at 1.5 or 0.75 mg, the injectable GLP-1 agonist exenatide at 10 mcg twice daily, or placebo
FDA Approval: Both Semaglutide (Ozempic/Wegovy) and Tirzepatide (Mounjaro/Zepbound) are FDA-approved for diabetes and weight loss
Cutting edge: CD69 interference with sphingosine-1-phosphate receptor function regulates peripheral T cell retention
Drinking alcoholic beverages while on this medication may increase the risk of developing hypoglycemia
